ArticleJTO clinical and research reports2022

First-Line Pembrolizumab Monotherapy for Advanced NSCLC With Programmed Death-Ligand 1 Expression Greater Than or Equal to 50%: Real-World Study Including Older Patients in Japan.

Yasushi Goto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.